Search Results - "Caram, Megan"

Depression, Anxiety, and Patterns of Mental Health Care Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy by Tsao, Phoebe A, Ross, Ryan D, Bohnert, Amy S B, Mukherjee, Bhramar, Caram, Megan E V

“…Androgen deprivation therapy (ADT) use is associated with an increased risk of developing depression and anxiety. Little is known about how the mental health…”
Get full text

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors by Cobain, Erin F, Wu, Yi-Mi, Vats, Pankaj, Chugh, Rashmi, Worden, Francis, Smith, David C, Schuetze, Scott M, Zalupski, Mark M, Sahai, Vaibhav, Alva, Ajjai, Schott, Anne F, Caram, Megan E V, Hayes, Daniel F, Stoffel, Elena M, Jacobs, Michelle F, Kumar-Sinha, Chandan, Cao, Xuhong, Wang, Rui, Lucas, David, Ning, Yu, Rabban, Erica, Bell, Janice, Camelo-Piragua, Sandra, Udager, Aaron M, Cieslik, Marcin, Lonigro, Robert J, Kunju, Lakshmi P, Robinson, Dan R, Talpaz, Moshe, Chinnaiyan, Arul M

“…Use of next-generation sequencing (NGS) to identify clinically actionable genomic targets has been incorporated into routine clinical practice in the…”
Get more information

The perfect storm by Caram, Megan E.V.

Get full text

Effects of Advanced Practice Providers on Single-specialty Surgical Practice by Hollenbeck, Brent K, Kaufman, Samuel R, Oerline, Mary, Modi, Parth K, Caram, Megan E V, Shahinian, Vahakn B, Ellimoottil, Chad

“…To assess the effects of adding advanced practice providers to surgical practices on surgical complications, readmissions, mortality, episode spending, length…”
Get full text

A Positive Distress Screen…Now What? An Updated Call for Integrated Psychosocial Care by Tsao, Phoebe A, Fann, Jesse R, Nevedal, Andrea L, Bloor, Lindsey E, Krein, Sarah L, Caram, Megan E V

“…How can we move collaborative care from evidence-based practice to everyday practice for those living with cancer and distress?…”
Get full text

Has Declining Opioid Dispensing to Cancer Patients Been Tailored to Risk of Opioid Harms? by Townsend, Tarlise N., Salz, Talya, Haffajee, Rebecca L., Caram, Megan E.V., Chino, Fumiko, Bohnert, Amy S.B.

“…Opioid prescribing to cancer patients is declining, but it is unknown whether reductions have been tailored to those at highest risk of opioid-related harms…”
Get full text

Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer by Caram, Megan E V, Ross, Ryan, Lin, Paul, Mukherjee, Bhramar

“…Sipuleucel-T is an immunotherapy that has been approved for use in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate…”
Get full text

Temporal and geographic variation in the systemic treatment of advanced prostate cancer by Caram, Megan E V, Estes, Jason P, Griggs, Jennifer J, Lin, Paul, Mukherjee, Bhramar

“…Several systemic treatments have been shown to increase survival for patients with metastatic castration-resistant prostate cancer. This study sought to…”
Get full text

Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer by Lai, Lillian Y, Oerline, Mary K, Caram, Megan E V, Tsao, Phoebe A, Kaufman, Samuel R, Hollenbeck, Brent K, Shahinian, Vahakn B

“…Abstract Background Abiraterone and enzalutamide are the most common oral agents for the treatment of men with advanced prostate cancer. To understand their…”
Get full text

The 340B Program and oral specialty drugs for advanced prostate cancer by Faraj, Kassem S., Kaufman, Samuel R., Oerline, Mary, Herrel, Lindsey A., Maganty, Avinash, Caram, Megan E. V., Shahinian, Vahakn B., Hollenbeck, Brent K.

“…Introduction Expensive oral specialty drugs for advanced prostate cancer can be associated with treatment disparities. The 340B program allows hospitals to…”
Get full text

A comparison of parametric propensity score‐based methods for causal inference with multiple treatments and a binary outcome by Yu, Youfei, Zhang, Min, Shi, Xu, Caram, Megan E. V., Little, Roderick J. A., Mukherjee, Bhramar

“…We consider comparative effectiveness research (CER) from observational data with two or more treatments. In observational studies, the estimation of causal…”
Get full text

Adherence and out‐of‐pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer by Caram, Megan E. V., Oerline, Mary K., Dusetzina, Stacie, Herrel, Lindsey A., Modi, Parth K., Kaufman, Samuel R., Skolarus, Ted A., Hollenbeck, Brent K., Shahinian, Vahakn

“…Background Abiraterone and enzalutamide are high‐cost oral therapies that increasingly are used to treat patients with advanced prostate cancer; these agents…”
Get full text

Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer by Faraj, Kassem S., Kaufman, Samuel R., Herrel, Lindsey A., Maganty, Avinash, Oerline, Mary K., Caram, Megan E. V., Shahinian, Vahakn B., Hollenbeck, Brent K.

“…Background Urologists practicing in single‐specialty groups with ownership in radiation vaults are more likely to treat men with prostate cancer. The effect of…”
Get full text

Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system by Herr, Daniel J, Elliott, David A, Duchesne, Gillian, Stensland, Kristian D, Caram, Megan E V, Chapman, Christina, Burns, Jennifer A, Hollenbeck, Brent K, Sparks, Jordan B, Shin, Chris, Zaslavsky, Alexander, Tsodikov, Alexander, Skolarus, Ted A

“…Accurate information regarding real-world outcomes after contemporary radiation therapy for localized prostate cancer is important for shared decision-making…”
Get full text

Addressing financial toxicity in cancer treatment-An opportunity for the 340B drug pricing program by Faraj, Kassem S, Caram, Megan E V, Shahinian, Vahakn B, Hollenbeck, Brent K

“…Cancer treatment has become increasingly expensive, partially due to the use of specialty drugs. The costs of these drugs are often passed down to patients,…”
Get full text

National Long-term Survival Estimates After Radical Prostatectomy for Prostate Cancer by Stensland, Kristian D., Caram, Megan E.V., Herr, Daniel J., Burns, Jennifer A., Sparks, Jordan B., Elliott, David A., Shin, Chris, Morgan, Todd M., Zaslavsky, Alexander, Hollenbeck, Brent K., Tsodikov, Alexander, Skolarus, Ted A.

“…To examine survival and disease control outcomes, including metastasis-related survival outcomes, in a large contemporary cohort of patients undergoing radical…”
Get full text

Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis by Caram, Megan E.V, Skolarus, Ted A, Cooney, Kathleen A

“…Take Home Message Prostate-specific antigen (PSA) is frequently used in isolation to guide treatment decisions in men with recurrent prostate cancer, a…”
Get full text

A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer by Tsung, Irene, Green, Edward, Palmbos, Phillip, Sloan, Zachery, Reichert, Zachery R, Vaishampayan, Ulka, Smith, David C, Caram, Megan E V, Yentz, Sarah, Daignault-Newton, Stephanie, Hurley, Laura, Nguyen, Charles B, Kraft, Shawna, Alva, Ajjai

“…Immune checkpoint inhibitor therapy and nab-paclitaxel have each shown efficacy in platinum-refractory advanced urothelial cancer. We conducted a single-arm…”
Get full text

Implications of the Merit-Based Incentive Payment System for Urology Practices by Maganty, Avinash, Hollenbeck, Brent K., Kaufman, Samuel R., Oerline, Mary K., Lai, Lillian Y., Caram, Megan E.V., Shahinian, Vahakn B.

“…To determine the implications of the merit-based incentive payment system (MIPS) for urology practices. MIPS is a Medicare payment model that determines…”
Get full text

Practice Competition and Treatment of Newly Diagnosed Prostate Cancer by Maganty, Avinash, Hollenbeck, Brent K., Kaufman, Samuel R., Oerline, Mary K., Lai, Lillian Y., Caram, Megan E.V., Shahinian, Vahakn B.

“…To examine the effect of urology practice market competition on use of treatment in men with newly diagnosed prostate cancer. We performed a retrospective…”
Get full text